FDAnews
www.fdanews.com/articles/192157-fda-finds-astrazenecas-farxiga-falls-short-for-type-1-diabetes
AstraZeneca

FDA Finds AstraZeneca’s Farxiga Falls Short for Type 1 Diabetes 

July 29, 2019

The FDA shot down AstraZeneca’s Farxiga (dapagliflozin) as an adjunct treatment to insulin for type 1 diabetes patients in a complete response letter to the company on Monday.

The once-daily oral medication is a selective SGLT2 inhibitor, one of a group of prescription drugs cleared by the agency for use in conjunction with dieting and exercise to lower blood sugar in adults with type 2 diabetes.

“The safety and efficacy of SGLT2 inhibitors have not been established in patients with type 1 diabetes, and FDA has not approved them for use in these patients,” the agency said.

View today's stories